Showing results (451-460 of 577) with videos related to
Sort By:
Pageof 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerDavid Cunningham, Ian Chau, Deborah D Stocken, et al.The Lancet. Oncology|September 22, 2014
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialHansjochen Wilke, Kei Muro, Eric Van Cutsem, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 27, 2012
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort StudyAnthony J Swerdlow, Rosie Cooke, Andrew Bates, et al.European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapyPaul Ruff, David R Ferry, Radek Lakomỳ, et al.Journal of Clinical Medicine|January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome SequencingIrene Y Chong, Naureen Starling, Alistair Rust, et al.Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.Journal for Immunotherapy of Cancer|December 11, 2021
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survivalManish A Shah, David Cunningham, Jean-Philippe Metges, et al.Lancet (London, England)|September 11, 2021
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Rogier Mous, Michael Roost Clausen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME studyJean-Yves Douillard, Salvatore Siena, James Cassidy, et al.Pageof 58